The Indonesia-connected healthcare market is projected to grow from $398.16 Mn in 2022 to $2941.56 Mn by 2030, registering a CAGR of 28.4% during the forecast period of 2022 - 2030. The main factors driving the growth would be rising healthcare spending, chronic disease burden, and government support. The market is segmented by type, function and by application. Some of the major players include Halodoc, Alodokter, SehatQ, Good Doctor, Medtronic and Honeywell.
By 2030, it is anticipated that the Indonesia Nutrition and Supplements market will reach a value of $xx Bn from $2.29 Bn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Nature’s Sunshine Products, Darya-Varia Laboratoria Tbk, and Citra Nusa Insan Cemerlang. The market for nutrition and supplements in Indonesia is primarily driven by government initiatives, increasing consumer awareness for health and lifestyle, and international supplements business. The Indonesia nutrition and supplements market in Indonesia is segmented by Type, Product, application, and Distribution Channel.
Indonesia's Dental Care Services Market size is at around $215.28 Mn in 2022 and is projected to reach $353.62 Mn in 2030, exhibiting a CAGR of 6.4% during the forecast period 2022 to 2030. The largest market of dental care in Asia, driven by aesthetic sensitive needs and a growing ageing population Japan is dominated by huge corporations J. Morita Corporation, Mitsui & Co., and GC Corporation. This report is segmented by treatment type, age group, clinical setup, and demography and provides in-depth insights into opportunities for expansion.
This report presents a strategic analysis of the Indonesia Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Indonesia Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
The Indonesia Central Nervous System (CNS)Therapeutics Market was valued at $1.260 Bn in 2022 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030, to $2.070 Bn by 2030. The key drivers of this industry include the rising prevalence of CNS disorders, improving healthcare access, and technological advancements. The industry is primarily dominated by players such as Abbott, Pfizer, Takeda, Merck, Eisai, AstraZeneca, and Novartis among others.
The Indonesia Cholesterol Therapeutics Market is anticipated to experience a growth from $146 Mn in 2022 to $179 Mn by 2030, with a CAGR of 2.6 % during the forecast period of 2022-2030. This market is driven by certain factors such as the increasing detection of cases due to more awareness, advancements in medical research and technology, and the favorable economic growth of the country which means increased purchasing power among the population. The Indonesia Cholesterol Therapeutics Market encompasses various players across different segments such as Pfizer, Merck, Roche, Novartis, Amgen, AstraZeneca, Kalbe Pharma, IndoPharma, Pharos, Bio Pharma, etc, among various others.
Indonesia Cardiac Resynchronization Therapy Market valued at $29 Mn in 2022, projected to reach $43 Mn by 2030 with a 5% CAGR. The global surge in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a significant catalyst contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major contributors to this market include companies such as Medtronic, Boston Scientific, Abbott, Siemens Healthineers, MicroPort Apsara, Lepu Medical Technology Co., Beijing Easywell Medical Device Co., Shenzhen Lepu Heart Valve Technology Co., Terumo Corporation, and Osram Health.
Indonesia Cancer Induced Bone Disease Therapeutics Market valued at $8 Mn in 2022, projected to reach $12 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include the rising incidence of cancers, government initiatives, and unmet medical needs. The industry is primarily dominated by players such as Roche, Bayer, Merck, Johnson & Johnson, Novartis, and Amgen among others.
This report presents a strategic analysis of the Indonesia Antiviral Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Indonesia Antiviral Drugs Market, offering unmatched value, accuracy and expert insights.
Indonesia alzheimer’s therapeutics market valued at $29 Mn in 2022, projected to reach $58 Mn by 2030 with a 9.1% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is one major factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently operating in the market are Eisai Co., Otsuka Pharmaceutical Co., Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co., Sanofi, PT Kalbe Farma and PT Kimia Farma.
Indonesia Infectious Disease Drugs Market valued at $0.71 Bn in 2023, projected to reach $0.95 Bn by 2030 with a 4.27% CAGR. The market is expanding as a result of government initiatives, changing demographics, and an increase in the prevalence of infectious diseases. The market is dominated by key players like Kalbe Farma, Bio Farma, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.
The Indonesia Atopic Dermatitis Therapeutics Market was valued at US $74 Mn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $145 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), growing disposable income and improved healthcare infrastructure. The industry is primarily dominated by players such as Sanofi, Novartis, Abbott, Merck, Roche, GSK, Bristol-Myers Squibb, among others.
Indonesia Atherosclerosis therapeutics market was valued at $17 Mn in 2022 and is estimated to reach $26 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The demand for atherosclerosis treatments is expected to rise due to the growing cases of cardiovascular diseases, escalated by unhealthy eating habits, inactive lifestyles, and a globally aging population. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, Sanofi, Merck, AstraZeneca, Bayer, PT Kalbe Farma, PT Kimia Farma, Eli Lilly and AbbVie.
The Indonesia Asthma and COPD Therapeutics Market was valued at US $200 Mn in 2022, and is predicted to grow at (CAGR) of 5.20% from 2023 to 2030, to US $301 Mn by 2030. The key drivers of this industry include the increasing prevalence of COPD and Asthma, rising economic growth, advancements in therapeutics, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Pfizer, GSK, Novartis, Abbott, and Boehringer Ingelheim, among others.
Indonesia HIV Drugs Market is at around $0.19 Bn in 2023 and is projected to reach $0.24 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like PT Dexa Medica, PT Sanbe Farma, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd.
Indonesia Antifungal Drugs Market is at around $0.09 Bn in 2023 and is projected to reach $0.12 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The industry is driven by rising healthcare spending, rising awareness and education, and technological advancements. The market is dominated by key players like Pfizer Inc., Novartis AG, Merck & Co., Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Indonesia Hepatitis C drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market will grow as a result of a number of factors, including the expansion of the pharmaceutical sector, an ageing population, growing healthcare expenditures, urbanisation, better monitoring and screening technologies, and a rise in liver cancer and cirrhosis fatalities brought on by HBV. Some of the major key players in this market are Bristol-Myers Squibb Company Gilead Sciences, Inc. Abbvie Kadmon Holdings Inc. F. Hoffmon La Roche Ltd. GlaxoSmithKline J & J Lupin Pharmaceuticals, Inc. Merck & Co., Inc. Teva Pharmaceuticals and Zydus Pharmaceuticals.
Indonesia HER-2 Negative Breast Cancer Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. A number of factors, such as age, obesity, alcoholism, radiation exposure history, family history of breast cancer, family history of the disease, age at first pregnancy, onset of the menstrual cycle, and tobacco use, increase the risk of developing the disease. As a result of lifestyle changes, the incidence and prevalence of breast cancer are rising quickly. All of this will drive a HER-2 Negative Breast Cancer Market.The global HER-2 Negative Breast Cancer market’s major key players are Pfizer, Novartis AG Merck & Co. Inc., GlasxoSmithKline, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca, Lupin, Bayer AG.
Indonesia herceptin biosimilar market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market grows as a result of increased research and development as well as rising public knowledge of cancer treatments. Additionally, rising healthcare costs and the existence of innovative pipeline products create an opportunity for market expansion. Some of the key players in this market are Mylan N.V., Amgen Inc., Mabion S.A., AryoGen Biopharma, Genor Biopharma, Celltrion Inc., Gedeon Richter Plc, The Instituto Vital Brazil, F. Hoffmann-La Roche AG, and Biocon.
Indonesia homeopathy product market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030.The market will increase significantly during the forecast period as a result of the ageing and growing paediatric populations. During the forecast period, rising use of homoeopathy as a holistic treatment is anticipated to drive market expansion. Some of the key players in this market are Boiron, Biologische Heilmittel Heel GmbH, A Nelson & Co Ltd, Homeocan, SBL, Hahnemann Laboratories, Medisynth, Ainsworths Ltd., Hevert - Arzneimittel GmbH & Co. KG.
Indonesia Human Insulin Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. An increasing number of people with diabetes, increased exposure to key diabetes risk factors, rising market demand for human insulin analogues, technological advancements in the field of human insulin delivery devices, and favourable medical reimbursements are all expected to lead to an increase in the global market for human insulin. Some of the key players in this market are Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), etc.
Indonesia Human Papillomavirus (HPV) vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for HPV vaccines is mainly being driven by the rising need for prevention of these infections as well as the rising prevalence of human papillomavirus (HPV)-related malignancies of the anus, vulva, vagina, penis, and oropharynx. Some of the key players in this market are Xenetic Biosciences, Inc., Bharat Biotech., AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd, Inovio Pharmaceuticals, Inc, Novartis AG, Sanofi, Merck & Co., Inc.
Indonesia human rotavirus vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing global supply of goods to comply with and meet the demands of immunisation strategies to eradicate endemic diseases is one of the major reasons boosting market expansion. Globally, there is more government control to ensure that everyone has access to low- or no-cost immunizations. All these factors will drive the growth of human rotavirus vaccine market. Some of the key players in this market are GlaxoSmithKline plc. (UK), Sanofi (France), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Emergent BioSolutions, Inc. (US), CSL Limited (Australia), Inovio Pharmaceuticals, Inc. (US), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan).
Indonesia immune checkpoint inhibitors market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for immune checkpoint inhibitors is expanding as a result of factors such as leading an unhealthy lifestyle, a rise in cancer incidence, and genetic mutation and alteration that have an impact on how much the nation's healthcare systems cost. Some of the global key players in this market are AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences.), Bristol-Myers Squibb Company, Roche Holding AG, Incyte Corporation, Novartis AG, etc.
Indonesia immunosuppressant drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The key factor fueling the growth of the immunosuppressants market is the rise in autoimmune illnesses like multiple sclerosis, alopecia areata, and arthritis. The market growth for immunosuppressants is also influenced by an increase in organ transplant procedures, such as kidney and liver transplants, which is brought on by an increase in the incidence of organ failure. Some of the major key players are Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.), Mylan N.V., AbbVie Inc., Sanofi S.A., GlaxoSmithKline Plc., Astellas Pharma Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer Inc., Novartis International AG (Sandoz), Bristol-Myers Squibb Company.